BACKGROUND: From animal studies, it is known that mastitic inflammation of the mammary lobes can produce proinflammatory cytokines and can damage the milk fat globule (MFG). OBJECTIVE: To investigate, in women, whether MFG and interleukin (IL)-6 differences are observed between mastitic milk (MM) and healthy milk (HM) of a mother. METHODS: MM was obtained from the specific nipple pore leading to the mastitic lobe of 17 women; HM was obtained from the other breast. Milk sampling occurred at days 0 (pre-treatment), 1, and 2 (post-treatment). MFG size and IL-6 were measured by laser light scattering and enzyme-linked immunosorbent assay, respectively. We analyzed MFG and IL-6 differences between HM and MM, whether any differences occurred over time with treatment, and whether differences were observed between mothers with systemic symptoms (fever/malaise, Group A) or without systemic symptoms (Group B). RESULTS: On day 0, MM had higher MFG size (P < .01) and IL-6 levels (P < .001) than HM. This difference significantly decreased over time with treatment for both MFG size (P < .01) and IL-6 (P < .05). On day 0, Group A mothers had significantly larger MFG size (P < .01) and IL-6 (P < .001) than Group B. CONCLUSIONS: MM contains larger MFG and higher IL-6 levels than milk from the healthy breast. This difference is larger if accompanied by systemic symptoms of mastitis (fever/malaise). These changes decreased over time with treatment. Therefore, early initiation of appropriate treatment may be useful in limiting the processes that contribute to alterations in MFG size and IL-6.
BACKGROUND: From animal studies, it is known that mastitic inflammation of the mammary lobes can produce proinflammatory cytokines and can damage the milk fat globule (MFG). OBJECTIVE: To investigate, in women, whether MFG and interleukin (IL)-6 differences are observed between mastitic milk (MM) and healthy milk (HM) of a mother. METHODS: MM was obtained from the specific nipple pore leading to the mastitic lobe of 17 women; HM was obtained from the other breast. Milk sampling occurred at days 0 (pre-treatment), 1, and 2 (post-treatment). MFG size and IL-6 were measured by laser light scattering and enzyme-linked immunosorbent assay, respectively. We analyzed MFG and IL-6 differences between HM and MM, whether any differences occurred over time with treatment, and whether differences were observed between mothers with systemic symptoms (fever/malaise, Group A) or without systemic symptoms (Group B). RESULTS: On day 0, MM had higher MFG size (P < .01) and IL-6 levels (P < .001) than HM. This difference significantly decreased over time with treatment for both MFG size (P < .01) and IL-6 (P < .05). On day 0, Group A mothers had significantly larger MFG size (P < .01) and IL-6 (P < .001) than Group B. CONCLUSIONS: MM contains larger MFG and higher IL-6 levels than milk from the healthy breast. This difference is larger if accompanied by systemic symptoms of mastitis (fever/malaise). These changes decreased over time with treatment. Therefore, early initiation of appropriate treatment may be useful in limiting the processes that contribute to alterations in MFG size and IL-6.
Authors: Marta Perez; Victor Ladero; Begoña Redruello; Beatriz Del Rio; Leonides Fernandez; Juan Miguel Rodriguez; M Cruz Martín; María Fernandez; Miguel A Alvarez Journal: PLoS One Date: 2016-09-01 Impact factor: 3.240
Authors: Lorena Ruiz; Irene Espinosa-Martos; Cristina García-Carral; Susana Manzano; Michelle K McGuire; Courtney L Meehan; Mark A McGuire; Janet E Williams; James Foster; Daniel W Sellen; Elizabeth W Kamau-Mbuthia; Egidioh W Kamundia; Samwel Mbugua; Sophie E Moore; Linda J Kvist; Gloria E Otoo; Kimberly A Lackey; Katherine Flores; Rossina G Pareja; Lars Bode; Juan M Rodríguez Journal: Front Immunol Date: 2017-06-30 Impact factor: 7.561
Authors: Kelley L Baumgartel; Maureen W Groer; Susan M Cohen; Dianxu Ren; Diane L Spatz; Yvette P Conley Journal: J Hum Lact Date: 2016-06-01 Impact factor: 2.219
Authors: Roxane Schaub; Stéphanie Badiou; Johannes Viljoen; Pierre Dujols; Karine Bolloré; Philippe Van de Perre; Marie-Louise Newell; Ruth Bland; Nicolas Nagot; Edouard Tuaillon Journal: J Transl Med Date: 2018-10-25 Impact factor: 5.531
Authors: Martyna Pajewska-Szmyt; Elena Sinkiewicz-Darol; Renata Gadzała-Kopciuch Journal: Environ Sci Pollut Res Int Date: 2019-01-28 Impact factor: 4.223